Timeline

  • 1979- Dyadic founded by Mark Emalfarb
  • 1980’s – Leading provider of pumice stones for the denim industry
  • Early 1990’s – Discovered the C1 microorganism (fungus) in Russia
  • 1994 – Began commercial production of industrial enzymes
  • 1996 – Began commercial production of industrial enzymes from the C1 fungus
  • 2003 – Establishes research and development facility in the Netherlands
  • 2004 – Establishes Scientific Advisory Board headed by Dr. Richard Lerner (former head of Scripps Research Institute)
  • 2004 – Raises approximately $26 million in private transactions
  • 2004 –  Becomes a publicly traded company
  • 2005 – Sequences the C1 genome
  • 2006 –  Partners with Scripps Florida to annotate the C1 genome
  • 2006 – Enters into R&D Agreement and Securities Purchase Agreement with Abengoa Bioenergy
  • 2006 – Raises approximately $26 million in private transactions
  • 2008 –  Enters into non-exclusive license agreement with Codexis, Inc. (biofuels partner of Shell)
  • 2009 – Enters into non-exclusive license agreement with Abengoa Bioenergy to use the C1 Platform Technology to produce biofuels, biochemicals and/or power
  • 2011 – Enters into research collaboration with Sanofi Pasteur to use the C1 Platform Technology to develop certain vaccines
  • 2011 – Enters into non-exclusive research and license agreement with a major company in the animal nutrition industry to use the C1 Platform Technology to develop and produce enzymes for use in animal feed
  • 2012 – Enters into non-exclusive research and license agreement with major company in the food industry to produce enzymes to produce certain food products
  • 2012 – Dyadic launches new product Fibrezyme® G5000
  • 2012 – Dyadic expands license agreement with Abengoa
  • 2012 – Dyadic was issued 3 new U.S. Patents
  • 2013 – Dyadic upgraded by OTC Markets to “Current Information” Tier
  • 2013 – Dyadic and BASF enter into a Research and Development Agreement
  • 2013 – Dyadic was issued one new U.S. Patent
  • 2014 – Dyadic expands its Dutch research centre
  • 2014 – Dyadic joins OTCQX Marketplace
  • 2014 – Dyadic announces participation in OPTIBIOCAT Collaboration
  • 2014 – Dyadic launches new product Fibrezyme® G4
  • 2014 – Dyadic strengthens European leadership team
  • 2014 – Dyadic appoints Michael Tarnok to Board of Directors
  • 2014 – Dyadic announces participation in Bakenzyme project
  • 2014 – Dyadic announces new CFO Thomas Dubinski
  • 2014 – Dyadic and CIMV enter into collaboration
  • 2014 – Dyadic files Form 10 Registration Statement